Cardiovascular Systems (CSII) Rating Reiterated by William Blair

William Blair reissued their market perform rating on shares of Cardiovascular Systems (NASDAQ:CSII) in a research report report published on Thursday, December 21st.

A number of other equities research analysts also recently commented on CSII. Citigroup started coverage on shares of Cardiovascular Systems in a research report on Thursday, September 21st. They issued a market perform rating for the company. Raymond James Financial began coverage on shares of Cardiovascular Systems in a research report on Friday, September 22nd. They set a market perform rating for the company. Zacks Investment Research downgraded shares of Cardiovascular Systems from a hold rating to a sell rating in a research report on Tuesday, October 10th. Finally, Needham & Company LLC reissued a buy rating and set a $37.00 price objective on shares of Cardiovascular Systems in a research report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $31.50.

Cardiovascular Systems (CSII) opened at $24.76 on Thursday. The stock has a market cap of $844.86, a P/E ratio of 1,238.00 and a beta of 2.53. The company has a current ratio of 4.30, a quick ratio of 3.83 and a debt-to-equity ratio of 0.18. Cardiovascular Systems has a 1-year low of $23.00 and a 1-year high of $33.11.

Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Wednesday, October 25th. The medical device company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. The company had revenue of $49.70 million during the quarter, compared to the consensus estimate of $51.00 million. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) earnings per share. sell-side analysts predict that Cardiovascular Systems will post -0.03 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Advisor Group Inc. lifted its stake in Cardiovascular Systems by 0.4% in the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock worth $263,000 after purchasing an additional 35 shares in the last quarter. Legal & General Group Plc raised its position in shares of Cardiovascular Systems by 2.9% during the 2nd quarter. Legal & General Group Plc now owns 7,763 shares of the medical device company’s stock valued at $249,000 after buying an additional 216 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Cardiovascular Systems by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,114 shares of the medical device company’s stock valued at $809,000 after buying an additional 299 shares in the last quarter. American Century Companies Inc. raised its position in shares of Cardiovascular Systems by 0.7% during the 2nd quarter. American Century Companies Inc. now owns 81,325 shares of the medical device company’s stock valued at $2,621,000 after buying an additional 568 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Cardiovascular Systems by 9.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 9,193 shares of the medical device company’s stock valued at $296,000 after buying an additional 800 shares in the last quarter. Institutional investors and hedge funds own 74.86% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cardiovascular Systems (CSII) Rating Reiterated by William Blair” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/01/14/cardiovascular-systems-csii-now-covered-by-analysts-at-william-blair-updated-updated-updated.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply